Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease In Vivo Budipine (s.c., 30 μg/24 h, 11 days) is a substrate of P-glycoprotein (P-gp) and is actively transported out of the brain through the blood–brain barrier back into the blood plasma . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male abcblab(-/-) mice Male abcblab(-/-) mice (n=8, weight 29.0 g) and FVB/N wild-type mice (n =8, weight 28.0 g) Dosage: 30 μg (Budipine is dissolved in 0.9% sodium chloride and 0.5% ethanol) Administration: subcutaneous injections, continuously delivered 30 μg over 24 h, 11 days Result: Increased the cerebrum concentration for 3.1 times high in knock-out mice after an 11-day continuous administration. Showed no significant differences in plasma, spleen, kidney and liver. Form:Solid IC50& Target:NMDA Receptor